Ipca Laboratories Ltd.

Transcription

1 Ipca Laboratories Ltd. Corporate Presentation Mar 2016

2 Company Overview Incorporation : 1949 Present Management : Since 1975 Total income F. Y : ` Crs / US$ 433 Mn Exports F. Y : ` Crs / US$ 288 Mn Number of Employees : 13,132 including 6050 in marketing and distribution Business Model : Fully integrated pharmaceutical company producing Branded and Generics Formulations, APIs and Intermediates

3 Five Years Highlights Domestic Income ( ` Crs ) , , , , Domestic Income (US $ Mn) Export Income ( ` Crs ) 1, , , , , Export Income (US $ Mn) Total Income ( ` Crs ) 2, , , , , Total Income (US $ Mn) Net Profit After Tax ( ` Crs ) Net Profit After Tax (US $ Mn)

4 Manufacturing Facilities Formulations

5 Manufacturing Facilities Formulations Location Dosage Form Approvals / Inspections Athal, Silvassa Tablets & Capsules UK-MHRA, TGA-Australia, MCC-South Africa, HPB-Canada, WHO-Geneva Ratlam, Madhya Pradesh Tablets, Liquids, Injectables & Ointments MCC-South Africa Kandla, Gujarat Betalactum Tablets, Capsules & Dry Syrups UK-MHRA, MCC-South Africa Silvassa * Under Import Alert Tablets & Capsules UK-MHRA, TGA-Australia, HPB-Canada, US-FDA*

6 Manufacturing Facilities Formulations Location Dosage Form Approvals / Inspections Dehradun, Uttaranchal Indore (SEZ), Madhya Pradesh Tablets & Cephalosporin Injectables Tablets & Capsules WHO-GMP UK-MHRA US-FDA* Sikkim Tablets & Capsules GMP Pithampur, Dhar, Madhya Pradesh High Potency Oral Solid Dosage WHO-GMP INVIMA Colombia Tarapur, Palghar Tablets * Under Import Alert

7 Manufacturing Facilities Active Pharmaceutical Ingredients (APIs)

8 Manufacturing Facilities APIs Location Ratlam, Madhya Pradesh Indore, Madhya Pradesh Ankleshwar, Gujarat Nandesari, Gujarat Aurangabad, Maharashtra Mahad, Maharashtra Approvals / Inspections TGA-Australia, EDQM, Danish Regulatory Authority, PMDA-Japan, WHO-Geneva, US-FDA* WHO-GMP PMDA Japan WHO-GMP WHO-GMP GMP Ranu (Tehsil Padra), Gujarat * Under Import Alert

9 Revenue Break-up

10 Revenue Break-up % 77% Total Revenue 24% 23% Formulations APIs 60% 51% Total Revenue 40% 49% Exports Domestic 65% 71% 84% 90% Exports 29% 35% Formulations APIs Domestic 16% 10% Formulations APIs

11 Revenue Break-up ` Crs Domestic Exports Total Domestic Exports Total Growth Branded Formulations % Generic Formulations % Total Formulations % API / Intermediates % Others Total Income % Growth 3.1% -18.5% -9.0%

12 Financials

13 F.Y F.Y ` Crs US$ Mn ` Crs US$ Mn Financials % Growth Total Income % EBIDT % EBIDT % 11.51% 16.96% PBT # % PBT % 3.85% 11.59% PAT # % PAT % 3.25% 8.29% # After forex Loss of ` Crs as against forex gain of Rs. ` 4.25 Crs for previous year.

14 Financials Profitability to Net Income FY FY FY PBIDT 11.51% 16.96% 24.89% PBT 3.85% 11.59% 19.45% PAT 3.25% 8.29% 14.76%

15 Financials Business Characteristics FY FY FY Return on Capital Employed % (PBIT / Capital Employed) 4.37% 12.71% 25.28% Return on Net Worth % (PAT / Net Worth) 3.97% 11.47% 24.09% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets / Total Long Term Borrowings) Long Term Debt Equity Ratio (Total Long Term Borrowings / Net Worth) Debtors Turnover Ratio (Days) (Trade Receivables / Turnover) x Creditors Turnover Ratio (Days) (Trade Payables / Purchases) x Inventory Turnover Ratio (Days) (Inventory / Turnover) x

16 Financials Growth FY FY FY Net Total Income -9.00% -4.20% 16.40% Domestic Sales 3.10% 15.30% 10.90% Export Sales % % 20.40% PBIDT % % 29.60% PBT % % 36.40% Net Profit % % 44.10%

17 Financials Contribution of Therapeutic Groups Therapeutic Segment Exports Domestic Exports Domestic 21% 36% Non Steroidal Anti-Inflammatory Drugs (NSAID) 25% 39% 30% 23% Cardiovasculars & Anti-Diabetics 31% 23% 24% 14% Anti-Malarials 17% 12% 11% 7% Anti-Bacterials 12% 6% 2% 5% Gastro-Intestinal (GI) Products 3% 5% 3% 3% Neuro Psychiatry 5% 3% 2% 4% Cough Preparations 2% 4% - 4% Dermatology - 4% - 2% Urology - 2% - 1% Neutraceuticals - 1% 7% 1% Others 5% 1% 100% 100% Total 100% 100%

18 Branded Formulations Domestic

19 Branded Formulations Domestic All India Rank ORG-IMS : 22nd (MAT Mar 16). 25 Depots & 2 C&F agents. 13 Therapy Focused Marketing Divisions. Field Strength (PSR/ BA) Over 2000 Wholesalers. 3 brands among top 300 brands (HCQS, Zerodol-P & Zerodol-SP). Market leaders in Anti-malarials & Rheumatoid Arthritis.

20 Branded Formulations Domestic CAGR = 11.20% ` Crs US$ 134 Mn ` Crs US$ 148 Mn ` Crs US$ 172 Mn ` Crs US$ 1854Mn Sales

21 Branded Formulations Domestic Future Growth Drivers The company introduced 19 new Brands in the India market during Clinical research as a tool to launch innovative combination formulations / NDDS. Strong Brand building with focused promotion. In licensing/ out licensing to build business in the promoted therapy. Portfolio optimization, strategies to identify need gaps to build, enter, maintain and exit approach.

22 International Business

23 International Business Exports to over 120 countries. Recognized Star Trading House. Among top 10 pharmaceutical exporters from India. 50% sales from exports. Field-force to promote brands in more than 30 countries of CIS, South East Asia, Middle East, Latin America and Africa.

24 International Business Marketing offices in Russia, Ukraine, Vietnam, Philippines, Kenya, Columbia, Sri Lanka, Malaysia and Nigeria (subsidiary company). Formulation dossiers for branded formulations registered in 62 countries.

25 International Business CAGR = -5.90% ` Crs US$ 315 Mn ` Crs US$ 262 Mn ` Crs US$ 268 Mn ` Crs US$ 218 Mn Sales

26 International Business Continent Continent-wise Exports (` Crs) Formulations Bulk Drugs / Intermediates Total % Contribution Europe % Africa % Americas % Asia % CIS % Australasia % Total %

27 International Formulations

28 International Formulations CAGR = -8.20% ` Crs US$ 224 Mn ` Crs US$ 182 Mn ` Crs US$ 189 Mn ` Crs US$ 141 Mn Sales

29 International Branded Formulations

30 International Branded Formulations CAGR = -5.60% ` Crs US$ 53 Mn ` Crs US$ 52 Mn ` Crs US$ 43 Mn ` Crs US$ 36 Mn Sales

31 International Branded Formulations Future Growth Drivers Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments. Geographical expansion in covered countries through additional field force. Expansion in business lines - Institutions and Distributors. Introduction of new products - Existing developed formulations are identified for registration and launch across all continents.

32 International Generics

33 International Generics CAGR = -9.10% ` Crs US$ 171 Mn Country Products Registered Products Under Registration ` Crs US$ 139 Mn ` Crs US$ 137 Mn United Kingdom / Europe 59 2 ` Crs US$ 105 Mn Australia / New Zealand South Africa Sales United States / Canada 31 27

34 International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. Most formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements.

35 International Generics Future Growth Drivers North America Strategic tie up with 3 marketing partners for sale/distribution of Generic formulations. 42 ANDAs filed of which 18 ANDAs are approved. 8 to 10 ANDAs targeted for filing for every year. 505 (b) (2) projects/ Sustained Release Formulations. Exploring contract development and manufacturing opportunities.

36 International APIs

37 International APIs CAGR = -0.98% ` Crs US$ 92 Mn ` Crs US$ 80 Mn ` Crs US$ 78Mn ` Crs US$ 77 Mn Sales

38 Sr. No. Name of the API US- FDA UK - MHRA Canada- HPFB WHO International APIs Drug Master Files Japan - PMDA Australia 1 Atenolol a a a CEP a 2 Artemether a 3 Artesunate a 4 Artesunate Sterile a 5 Amodiaquine Hcl a EDQM - Europe 6 Amlodipine Besylate a a 7 Allopurinol a a CEP a 8 Beventalol Hcl a 9 Benzarone a 10 Benzbromarone a 11 Bendroflumethiazide a 12 Bisoprolol Fumarate a a 13 Carvedilol a a a 14 Cetrizine Dihydrochloride a CEP a 15 Chloroquine Phosphate a a

39 International APIs Drug Master Files US- UK - Sr. No. Name of the API FDA MHRA 16 Chloroquine Sulphate a Canada- HPFB WHO Japan - PMDA Australia EDQM - Europe 17 Chlorthalidone a a a 18 Cilostazole a 19 Citalopram HBR a 20 Dihydroartemesinin a 21 Etodolac a a 22 Famotidine a a 23 Fenofibrate a a 24 Fluconazole a 25 Flumequine a 26 Furosemide a a a CEP a 27 Glimepiride a a a 28 Hydrochlorothiazide a a a CEP a 29 Hydroxyzine Di Hcl a a 30 Hydroxychloroquine Sulphate a a a a

40 International APIs Drug Master Files Sr. No. Name of the API US- FDA UK - MHRA Canada- HPFB WHO Japan - PMDA Australia EDQM - Europe 31 Indapamide a a a 32 Losartan Potassium a a CEP a 33 Lumefantrine a 34 Methylphenidate a a 35 Mesalamine/ Mesalazine a a 36 Metformin HCL a a a 37 Metoclopramide HCl a a CEP a 38 Metoclopramide Base a 39 Metoprolol Succinate a a 40 Metoprolol Tartrate a a a a 41 Midodrine Hydrochloride a 42 Nabumetone a a 43 Nifedipine a a 44 Ondansetron Hydrochloride a a a 45 Ondansetron Base a

41 Sr. No. Name of the API Pantoprazole Sodium 46 Sesquihydrate US- FDA UK - MHRA Canada- HPFB WHO International APIs Drug Master Files Japan - PMDA Australia EDQM - Europe a 47 Paroxetine Hcl a 48 Perindopril a 49 Primaquine Phosphate a a 50 Piperaquine Phosphate a 51 Probenecid a 52 Proguanil Hydrochloride a a 53 Propranolol HCl a a a CEP a 54 Pyrantel Pamoate a a a a 55 Pyrimethamine Hcl a a 56 Promethazine Hydrochloride a 57 Quetiapine Fumarate a a 58 Risperidone a 59 Residronate Sodium a 60 Ractopamine Hcl a a

42 International APIs Drug Master Files Sr. No. Name of the API US- FDA UK - MHRA Canada- HPFB WHO Japan - PMDA Australia EDQM - Europe 61 Sodium Alendronate a a a 62 Sulfadoxine a 63 Telmisartan a 64 Torsemide a a 65 Tramadol Hydrochloride a a a 66 Trimethoprim a a CEP a 67 Triamterene a a 68 Triclabendazole a 69 Valsartan a a 70 Warfarin Sodium Clathrate a a 71 Warfarin Sodium CEP a 72 Zaltoprofen a 73 Zoledronic Acid a Total Note : Australia accept CEP isued by EDQM

43 International APIs Future Growth Drivers Pursuing MNC tie-ups for supply agreements. Non-infringing process Patent filed for APIs.

44 International APIs Future Growth Drivers Own API manufacturing to back formulations, especially for the Generic market. Exploring strategic business relationship with smaller API manufacturers for increasing product basket.

45 Research & Development APIs & Formulations

46 Research & Development APIs & Formulations R & D Spending Year ` Crs % to Sales % % % % %

47 Research & Development APIs & Formulations Current scientist manpower of over 800. Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 228 patent applications filed.

48 Research & Development APIs & Formulations Future Strategy Bio-tech / fermentation research facility established and working under contract research on two products. Undertaking contract research activities for APIs & Formulations for international clients.

49 Thank you No part of this corporate presentation may be re-produced, quoted or circulated without prior approval of Ipca Laboratories Limited. This presentation may include forward looking statements based on our current business expectations. Our actual results may differ from what is projected in this corporate presentation. The viewers of this presentation may use their own judgment and calculation before making any decision on any matter based on the information given herein. The company also disclaims any obligation to revise any of the information given in this presentation.